Lineage Cell Therapeutics :
Clinical-stage cell therapy. Programs are based on its proprietary cell-based therapy platform and associated development and manufacturing capabilities. Currently has 3 clinical programs: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Ph 1/2a development for dry AMD; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Ph 1/2a development for acute spinal cord injuries; and (iii) VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in Ph 1 for NSCLC.
100MM - 500MM
1010 Atlantic Avenue, Suite 102
Alameda, CA 94501-1147
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Upcoming Company Event Participation
Solebury Trout KOL Day
New York City,
November 15, 2019
Stock Market Data
Market Data copyright © 2019 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by